TY - JOUR T1 - The Role of <em>IL-10</em> Promoter Polymorphisms in Renal Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2205 LP - 2209 VL - 36 IS - 5 AU - WEN-SHIN CHANG AU - CHENG-HSI LIAO AU - CHIA-WEN TSAI AU - PEI-SHIN HU AU - HSI-CHIN WU AU - SHIH-WEI HSU AU - HONG-XUE JI AU - CHIEH-LUN HSIAO AU - DA-TIAN BAU Y1 - 2016/05/01 UR - http://ar.iiarjournals.org/content/36/5/2205.abstract N2 - Background/Aim: Renal cell carcinoma (RCC) accounts for approximately 3% of all cancer-related mortalities worldwide and the risk factors for the development of RCC have not yet been fully elucidated. Mounting proteomic evidence suggests that inflammatory process plays a role in RCC etiology and interleukin-10 (IL-10) is an important immunosuppressive cytokine. However, little is known on the contribution of IL-10 genotypes to RCC. This study aimed at evaluating the contribution of IL-10 promoter A-1082G (rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic polymorphisms to the risk of RCC in Taiwan. Materials and Methods: Associations of the three IL-10 polymorphic genotypes with the risk of RCC were examined among 92 RCC patients and 580 age- and gender-matched cancer-free controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The pilot results showed that the percentages of TT and TC for IL-10 T-819C genotypes were significantly higher in the RCC patient group than those in the healthy control group. The CC genotype carriers were of lower risk for RCC (odds ratio (OR)=0.33, 95% confidence interval (CI)=0.12-0.93, p=0.0369). There is no difference in the distribution of A-1082G or A-592C genotype between the RCC and control groups. Conclusion: The CC genotype of IL-10 T-819C genotype may have a protective effect on RCC risk in Taiwan. Further investigation with larger sample size in addition to genotype-phenotype correlation and intracellular mechanisms are our future work. ER -